| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Boc-Propargylamine does not have a defined pharmacological target. It is a chemical reagent used for the preparation of triazolobenzylidene-thiazolopyrimidines which act as CDC25 phosphatase inhibitors. CDC25 phosphatases are key regulators of cell cycle progression and are targets for cancer therapy. The compound is also used in the synthesis of β-glucan polysaccharide analogs and in Pauson-Khand reactions.
|
|---|---|
| ln Vitro |
Using N-Boc-propargylamine, triazolobenzylidene-thiazolopyrimidines are prepared. functions as an inhibitor of CDC25 phosphatase. It is also employed in the manufacture of analogues of beta-glucan polysaccharides. Furthermore, it takes part in the Pauson-Kh and (PK) reactions between N-Boc-propargylamine and norbornadiene to produce 4,5-disubstituted cyclopentenones.
In vitro, Boc-propargylamine is primarily used as a chemical reagent and synthetic intermediate. It is used in the preparation of triazolobenzylidene-thiazolopyrimidines as CDC25 phosphatase inhibitors. The compound is also involved in Pauson-Khand reactions with norbornadiene to prepare 4,5-disubstituted cyclopentenones. Additionally, it is used in the synthesis of β-glucan polysaccharide analogs. |
| ln Vivo |
In vivo data for Boc-propargylamine as a therapeutic agent are not available, as the compound is a chemical reagent used for synthesis. Its in vivo relevance is primarily indirect, through the biological activities of the final pharmaceutical compounds derived from its propargylamine scaffold, such as CDC25 phosphatase inhibitors.
|
| Enzyme Assay |
For in vitro chemical synthesis, Boc-propargylamine is used as a building block for the preparation of various compounds. Standard protocols involve reacting the terminal alkyne with azides in copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry reactions. The Boc-protected amine can be deprotected under acidic conditions to reveal the free amine for further functionalization. The compound is also used in Pauson-Khand reactions with alkenes and alkynes.
|
| Cell Assay |
For in vitro cell-based experiments, Boc-propargylamine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium.
|
| Animal Protocol |
In vivo animal studies using Boc-propargylamine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For CDC25 phosphatase inhibitors and other anticancer agents derived from this building block, efficacy studies would typically be performed in mouse xenograft models of cancer. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with measurement of tumor volume over time.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Boc-propargylamine as a standalone compound are not characterized in the literature. The compound has a molecular weight of 155.19 g/mol, which is favorable for oral bioavailability. The compound should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 1 year, kept away from direct sunlight.
|
| Toxicity/Toxicokinetics |
Boc-Propargylamine is a research chemical and should be handled with appropriate laboratory safety precautions. As a chemical reagent, it may cause skin and eye irritation. The compound should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 1 year, kept away from direct sunlight. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature.
|
| Additional Infomation |
Boc-Propargylamine (N-Boc-propargylamine, CAS 92136-39-5) is primarily a research-grade chemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a building block for the preparation of triazolobenzylidene-thiazolopyrimidines as CDC25 phosphatase inhibitors, in the synthesis of β-glucan polysaccharide analogs, and in Pauson-Khand reactions. No clinical trials or approved therapeutic indications exist for this compound.
|
| Molecular Formula |
C8H13NO2
|
|---|---|
| Molecular Weight |
155.19
|
| Exact Mass |
155.094
|
| CAS # |
92136-39-5
|
| PubChem CID |
11073648
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
222.5±23.0 °C at 760 mmHg
|
| Melting Point |
40-44ºC
|
| Flash Point |
88.4±22.6 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.452
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
11
|
| Complexity |
182
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)NCC#C
|
| InChi Key |
DSPYCWLYGXGJNJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H13NO2/c1-5-6-9-7(10)11-8(2,3)4/h1H,6H2,2-4H3,(H,9,10)
|
| Chemical Name |
tert-butyl N-prop-2-ynylcarbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4437 mL | 32.2186 mL | 64.4371 mL | |
| 5 mM | 1.2887 mL | 6.4437 mL | 12.8874 mL | |
| 10 mM | 0.6444 mL | 3.2219 mL | 6.4437 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
